JP2008517913A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517913A5
JP2008517913A5 JP2007537951A JP2007537951A JP2008517913A5 JP 2008517913 A5 JP2008517913 A5 JP 2008517913A5 JP 2007537951 A JP2007537951 A JP 2007537951A JP 2007537951 A JP2007537951 A JP 2007537951A JP 2008517913 A5 JP2008517913 A5 JP 2008517913A5
Authority
JP
Japan
Prior art keywords
group
compound according
compound
amino
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007537951A
Other languages
English (en)
Japanese (ja)
Other versions
JP4945453B2 (ja
JP2008517913A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/037271 external-priority patent/WO2006047124A1/en
Publication of JP2008517913A publication Critical patent/JP2008517913A/ja
Publication of JP2008517913A5 publication Critical patent/JP2008517913A5/ja
Application granted granted Critical
Publication of JP4945453B2 publication Critical patent/JP4945453B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007537951A 2004-10-25 2005-10-18 M4ムスカリン性受容体のアロステリック増強剤としてのチエノピリジン Expired - Fee Related JP4945453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62178504P 2004-10-25 2004-10-25
US60/621,785 2004-10-25
PCT/US2005/037271 WO2006047124A1 (en) 2004-10-25 2005-10-18 Thienopyridines as allosteric potentiators of the m4 muscarinic receptor

Publications (3)

Publication Number Publication Date
JP2008517913A JP2008517913A (ja) 2008-05-29
JP2008517913A5 true JP2008517913A5 (enExample) 2008-10-23
JP4945453B2 JP4945453B2 (ja) 2012-06-06

Family

ID=36021809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537951A Expired - Fee Related JP4945453B2 (ja) 2004-10-25 2005-10-18 M4ムスカリン性受容体のアロステリック増強剤としてのチエノピリジン

Country Status (16)

Country Link
US (1) US8071776B2 (enExample)
EP (1) EP1807434B1 (enExample)
JP (1) JP4945453B2 (enExample)
CN (1) CN100577666C (enExample)
AT (1) ATE478876T1 (enExample)
AU (1) AU2005299957B2 (enExample)
BR (1) BRPI0517438A (enExample)
CA (1) CA2583550C (enExample)
CY (1) CY1111477T1 (enExample)
DE (1) DE602005023197D1 (enExample)
DK (1) DK1807434T3 (enExample)
ES (1) ES2349416T3 (enExample)
MX (1) MX2007004794A (enExample)
PL (1) PL1807434T3 (enExample)
PT (1) PT1807434E (enExample)
WO (1) WO2006047124A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656972T3 (es) * 2012-02-23 2018-03-01 Vanderbilt University Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
EP3008073B1 (en) 2013-06-11 2020-01-01 Latvian Institute Of Organic Synthesis Thieno[2,3-b]pyridines as multidrug resistance modulators
WO2015027214A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
FI3474846T3 (fi) 2016-06-22 2023-02-16 Univ Vanderbilt Muskariinisen asetyylikoliinireseptorin m4 positiiviset allosteeriset modulaattorit
MX386258B (es) 2016-07-01 2025-03-18 Pfizer Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
EP3534901B1 (en) 2016-11-07 2022-06-22 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
MA47126A (fr) 2016-11-07 2019-10-30 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
CN109863139B (zh) * 2016-11-07 2023-02-17 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
PL3642202T3 (pl) 2017-06-22 2023-03-13 Pfizer Inc. Pochodne dihydropirolopirydyny
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
WO2019113174A1 (en) 2017-12-05 2019-06-13 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2025201078A1 (zh) * 2024-03-25 2025-10-02 四川科伦药物研究院有限公司 化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
WO1996003377A1 (en) * 1994-07-27 1996-02-08 Sankyo Company, Limited Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
GB9924962D0 (en) * 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
AU5919001A (en) * 2000-04-28 2001-11-12 Acadia Pharm Inc Muscarinic agonists
EP1478646A1 (en) * 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses

Similar Documents

Publication Publication Date Title
JP2008517913A5 (enExample)
TWI455939B (zh) cMET抑制劑
JP2009524676A5 (enExample)
JP2010509356A5 (enExample)
JP2004516314A5 (enExample)
JP2014513139A5 (enExample)
JP2013510124A5 (enExample)
JP2011526926A5 (enExample)
JP2015506348A5 (enExample)
JP2019512535A5 (enExample)
TW200621762A (en) Novel compounds
JP2010155827A5 (enExample)
JP2006520805A5 (enExample)
NZ586579A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2006122806A3 (en) 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
JP2013529196A5 (enExample)
JP2012512158A5 (enExample)
JP2013542261A5 (enExample)
JP2013514980A5 (enExample)
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
WO2007044050A3 (en) 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
JP2017517579A5 (enExample)
JP2018534314A5 (enExample)
RU2012125152A (ru) Способы и композиции, предназначенные для лечения солидных опухолей и других злокачественных новообразований